In Vitro Characterization of the Antibacterial Spectrum of Novel Bacterial Type II Topoisomerase Inhibitors of the Aminobenzimidazole Class
- 1 April 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (4) , 1228-37
- https://doi.org/10.1128/aac.50.4.1228-1237.2006
Abstract
Antibiotics with novel mechanisms of action are becoming increasingly important in the battle against bacterial resistance to all currently used classes of antibiotics. Bacterial DNA gyrase and topoisomerase IV (topoIV) are the familiar targets of fluoroquinolone and coumarin antibiotics. Here we present the characterization of two members of a new class of synthetic bacterial topoII ATPase inhibitors: VRT-125853 and VRT-752586. These aminobenzimidazole compounds were potent inhibitors of both DNA gyrase and topoIV and had excellent antibacterial activities against a wide spectrum of problematic pathogens responsible for both nosocomial and community-acquired infections, including staphylococci, streptococci, enterococci, and mycobacteria. Consistent with the novelty of their structures and mechanisms of action, antibacterial potency was unaffected by commonly encountered resistance phenotypes, including fluoroquinolone resistance. In time-kill assays, VRT-125853 and VRT-752586 were bactericidal against Staphylococcus aureus , Streptococcus pneumoniae , Enterococcus faecalis , and Haemophilus influenzae , causing 3-log reductions in viable cells within 24 h. Finally, similar to the fluoroquinolones, relatively low frequencies of spontaneous resistance to VRT-125853 and VRT-752586 were found, a property consistent with their in vitro dual-targeting activities.Keywords
This publication has 26 references indexed in Scilit:
- Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997–2003)Diagnostic Microbiology and Infectious Disease, 2005
- Crystal Structures of Escherichia coli Topoisomerase IV ParE Subunit (24 and 43 Kilodaltons): a Single Residue Dictates Differences in Novobiocin Potency against Topoisomerase IV and DNA GyraseAntimicrobial Agents and Chemotherapy, 2004
- Drug‐Resistant Pneumococcal Pneumonia: Clinical Relevance and Related FactorsClinical Infectious Diseases, 2004
- Antibacterials: are the new entries enough to deal with the emerging resistance problems?Current Opinion in Biotechnology, 2003
- Inhibitors of Bacterial Topoisomerases: Mechanisms of Action and Resistance and Clinical Aspects1Planta Medica, 2001
- DNA Topoisomerases: Structure, Function, and MechanismAnnual Review of Biochemistry, 2001
- Topoisomerase IV, alone, unknots DNA in E. coliGenes & Development, 2001
- Roles of Topoisomerases in Maintaining Steady-state DNA Supercoiling in Escherichia coliJournal of Biological Chemistry, 2000
- New topoisomerase essential for chromosome segregation in E. coliCell, 1990
- The slow-binding and slow, tight-binding inhibition of enzyme-catalysed reactionsTrends in Biochemical Sciences, 1982